U.S. Markets closed

Ortho Regenerative Technologies Inc. (ORTIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.5703-0.0227 (-3.83%)
At close: 3:05PM EST
Full screen
Loading interactive chart...
  • ORTH.CN: OrthoRTI & Hanuman Partner on Buoy-Based PRP Prep
    Zacks Small Cap Research

    ORTH.CN: OrthoRTI & Hanuman Partner on Buoy-Based PRP Prep

    By John Vandermosten, CFA CNSX:ORTH.CN | OTC:ORTIF READ THE FULL ORTH.CN RESEARCH REPORT Ortho Regenerative Technologies (CNSX:ORTH) (OTC:ORTIF) announced on January 5, 2021 it had entered into an agreement with Hanuman Pelican, Inc. providing Ortho global rights (excluding Japan) to commercialize Hanuman’s Buoy Suspension Fractional System as a part of a turnkey offering for Ortho-R. The deal

  • Ortho Regenerative Technologies Enters Into Global License With Hanuman Pelican, Inc.
    PR Newswire

    Ortho Regenerative Technologies Enters Into Global License With Hanuman Pelican, Inc.

    Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTCQB: ORTIF) ("Ortho RTI" or the "Company"), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that it has entered into a global licensing agreement (the "Agreement") with Hanuman Pelican Inc. ("Hanuman") for the use of the Buoy Suspension Fractional System in combination with Ortho-R, Ortho RTI's lead Chitosan-PRP hybrid drug/biologic implant combination product.

  • ORTH.CN: Meniscus Plan In Place
    Zacks Small Cap Research

    ORTH.CN: Meniscus Plan In Place

    By John Vandermosten, CFA CNSX:ORTH.CN | OTC:ORTIF READ THE FULL ORTH.CN RESEARCH REPORT Third Quarter Fiscal Year 2021 Operational and Financial Results Ortho Regenerative Technologies Inc. (CNSX:ORTH.CN) (OTC:ORTIF) reported third quarter fiscal year 2021 financial and operational results and submitted its SEDAR filings on December 18, 2020. During 3Q:21, extending from August 1 to